Revolution Medicines to Host Four ESMO Data Presentations on RAS(ON) Inhibitors
Jun 24, 2026, 7:33 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
ESMO data events typically provide sentiment and price sensitivity for biotech names with late-stage or near-term readouts. Positive signals or strong presentations can re-rate growth potential, though actual data are not disclosed yet and results could disappoint. Historical analogs show stock moves around conference data even before ensembling results, especially for PDAC-focused programs with credible KOLs presenting.
AI summary
What happened, with direct paths to the underlying reporting
Revolution Medicines announced four data presentations at the ESMO Gastrointestinal Cancers Congress (July 1–4, 2026) in Munich, including two oral zoldonrasib (RMC-9805) studies in 1L and 2L PDAC and two Phase 3 posters for RASolute 303/304. The data explore zoldonrasib with chemotherapy and in combination with daraxonrasib, plus adjuvant daraxonrasib in PDAC. While no results are disclosed yet, positive signals could influence RVMD's valuation and near-term sentiment ahead of potential readouts.
Revolution Medicines will present four data items at ESMO GI Congress, July 1–4, 2026.
Two oral zoldonrasib (RMC-9805) PDAC data sets in 1L and 2L settings.
RASolute 303 and RASolute 304 Phase 3 posters in metastatic and adjuvant PDAC.
Presentations include zoldonrasib plus chemotherapy and zoldonrasib plus daraxonrasib.
Positive reads could lift RVMD sentiment ahead of potential clinical readouts.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Regulatory progress for Revolution Medicines' pancreatic cancer program emerged as the EMA initiated a rolling review of the company's experimental therapy. While not a guarantee…
Revolution Medicines reported Phase 3 RASolute 302 results for daraxonrasib in metastatic pancreatic cancer, showing statistically significant OS and PFS improvements versus stand…
U.S. cancer centers are actively enrolling patients in an early access program for a promising pancreatic cancer treatment from Revolution Medicines, pending expected FDA approval…
Revolution Medicines announced significant survival benefits from the daraxonrasib trial, expected to be submitted to the FDA as a New Drug Application. Following substantial fund…
